Literature DB >> 26042444

Imaging guided mediastinal percutaneal core biopsy--technique and complications.

T Azrumelashvili1, M Mizandari1, D Magalashvili1, T Dundua1.   

Abstract

165 percutaneous biopsies of anterior, middle and posterior mediastinum lesions were performed to 156 patients. Procedure was guided by US in 40 cases, by CT - in 125 cases. Hydrodissection was used in 5 cases, artificial pneumothorax - in 3 cases in order to avoid transpulmonary needle pass. Post-biopsy CT scan was performed and patients observed for any complications. Adequate tissue for histological diagnosis was obtained in 156 (94.5%) cases at the first attempt; in 9 (5.5%) cases the repeated procedure was needed. No major complications were detected after biopsy procedures; minor complications (pneumothorax, hemothorax and hemophtysis) were detected in 23 (13.9%) cases. No complications were detected after US guided procedures; In 17 (10.3% of all complications) cases pneumothorax, in 4 (2.4%) cases - hemothorax and in 2 (1.2%) cases hemophtisis was detected on CT guided procedures. All hemothorax and hemophtisis and 10 pneumothorax cases happened to be self-limited; in 3 pneumothorax cases aspiration and in 4 cases - pleural drainage was needed. Percutaneous image-guided core biopsy of mediastinal lesions is an accurate and safe procedure, which enables to get the tissue material from all mediastinum compartments. Ultrasound is the most efficient for biopsy guidance, if the target is adequately imaged by it; the advantages of US guidance are: a) possibility of real-time needle movement control b) possibility of real-time blood flow imaging b) noninvasiveness c) cost-effectiveness d) possibility to perform the biopsy at the bedside, in a semiupright position; so, ultrasound is a "Gold Standard" for procedure guidance if the 'target" can be adequately imaged by this technique. If US guidance is impossible biopsy should be performed under CT guidance. Hydrodissection and artificial pneumothorax enables to avoid the lung tissue penetration related complications. Pneumothorax was associated with multiple Needle passes and larger diameter needle use. The safety and biopsy procedure success high rate proves the use of IGMPCB as a first choice procedure when the mediastinal mass morphology is needed.

Entities:  

Mesh:

Year:  2015        PMID: 26042444

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  5 in total

1.  Clinical value of contrast-enhanced ultrasound in improving diagnostic accuracy rate of transthoracic biopsy of anterior-medial mediastinal lesions.

Authors:  Jingjing Fu; Wei Yang; Song Wang; Jing Bai; Hao Wu; Haiyue Wang; Kun Yan; Minhua Chen
Journal:  Chin J Cancer Res       Date:  2016-12       Impact factor: 5.087

2.  An initial experience of computed tomography-guided trans superior vena caval biopsy: a novel approach for precarious mediastinal lesions.

Authors:  Muthusubramanian Rajasekaran; Salil Pandey; Suresh Ashwathappa; Ganesh Subramanya Mandakulutur; Shashidhar V Karpurmath; Manjunath Irappa Nandennavar
Journal:  Pol J Radiol       Date:  2022-04-25

3.  Clinical value of contrast-enhanced ultrasound in transthoracic biopsy of malignant anterior mediastinal masses.

Authors:  Jie Han; Xiao-Li Feng; Tian-Yu Xu; Wen-Qi Feng; Meng-Jia Liu; Bo Wang; Ting-Lin Qiu; Yong Wang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Percutaneous CT Fluoroscopy-Guided Core Needle Biopsy of Mediastinal Masses: Technical Outcome and Complications of 155 Procedures during a 10-Year Period.

Authors:  Caroline Burgard; Robert Stahl; Giovanna Negrao de Figueiredo; Julien Dinkel; Thomas Liebig; Dania Cioni; Emanuele Neri; Christoph G Trumm
Journal:  Diagnostics (Basel)       Date:  2021-04-26

5.  Contrast-Enhanced Ultrasound Improves the Pathological Outcomes of US-Guided Core Needle Biopsy That Targets the Viable Area of Anterior Mediastinal Masses.

Authors:  Jian-Hua Zhou; Hong-Bo Shan; Wei Ou; Yun-Xian Mo; Jin Xiang; Yu Wang; Jian Li; Si-Yu Wang
Journal:  Biomed Res Int       Date:  2018-01-18       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.